Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Kairos Pharma, LTD.

Get SEC filing alerts via email and in your feed for Kairos Pharma, LTD.

KAPA

Kairos Pharma, LTD.

About Kairos Pharma, LTD.

Kairos Pharma is a clinical-stage biopharmaceutical company developing innovative cancer therapies targeting immune suppression and drug resistance. Its portfolio includes antibodies and small molecules for prostate, lung, breast cancers, and glioblastoma. Leveraging proprietary technologies licensed from Cedars-Sinai, the company focuses on immunotherapies that modulate tumor microenvironments, address resistance mechanisms, and enhance immune response, aiming to transform cancer treatment through novel, targeted drug development.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Kairos Pharma, LTD.

1
1
Kairos Pharma, LTD. Kairos Pharma Reports $1.654 Million Net Loss in Q1 2026, No Revenue Generated

Via official filing (AI summary) | 22 days ago | 0 comments

2
1
Kairos Pharma, LTD. Kairos Pharma Reports No Revenue and $5.45 Million Net Loss in Annual Filing

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
Kairos Pharma, LTD. Kairos Pharma Reports $1.4 Million Net Loss in Q3 2025, Increases Operating Expenses

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Kairos Pharma, LTD. Kairos Pharma Reports Increased Net Loss and Operating Expenses for First Half of 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Kairos Pharma, LTD. Kairos Pharma Reports $1.262 Million Net Loss in Q1 2025, No Revenue Generated

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Kairos Pharma, LTD. Kairos Pharma Reports $2.6 Million Net Loss for 2024, Completes IPO and Secures Financing

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Kairos Pharma, LTD. Kairos Pharma Reports Significant Financial Improvements and Strategic Agreements in Latest Quarter

Via official filing (AI summary) | over 1 year ago | 0 comments